T. Rowe Price Associates
NXTC icon

T. Rowe Price Associates’s NextCure NXTC Stock Holding History

T. Rowe Price Associates’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,033
Closed -$124K – 2946
2021
Q1 		$124K Buy
1,033
+1
+0.1% +$145 ﹤0.01% 2764
2020
Q4 		$135K Buy
+1,032
New +$133K ﹤0.01% 2602
2020
Q2 		– Sell
-1,321
Closed -$588K – 2529
2020
Q1 		$588K Buy
+1,321
New +$706K ﹤0.01% 1904

Other funds holding NXTC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

T. Rowe Price Associates's NXTC Position: Q2 2021 in Review

T. Rowe Price Associates sold out of NextCure (NXTC) in Q2 2021, closing a stake of 1,033 shares — an estimated $124K sold.

T. Rowe Price Associates first reported a position in NXTC in Q1 2020 and held it in 3 quarters. The position peaked at $588K in Q1 2020. 78 funds tracked by Wall St. Rank hold NXTC as of Q2 2021.

  • T. Rowe Price Associates reported no remaining NextCure position as of Q2 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,033 NextCure shares in Q2 2021, an estimated $124K.
  • T. Rowe Price Associates first reported a position in NextCure in Q1 2020 and held it in 3 quarters.
  • T. Rowe Price Associates's NextCure position peaked at $588K in Q1 2020.
  • 78 funds tracked by Wall St. Rank held NextCure as of Q2 2021.

Based on T. Rowe Price Associates's 13F filing for Q2 2021, filed 16 Aug 2021.